secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARYA Sciences Acquisition Corp IV (—)
CIK:        0001838821
Form:       8-K
Filed at:   2023-04-05T23:59:59+00:00
Accession:  0001140361-23-016524
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 4.02
LLM model:  deepseek-v4-flash:cloud@v2

ARYA Sciences restates Q3 2022 financials; underwriter commission waiver misclassified as gain rather than equity credit
--------------------------------------------------------------------------------

- Restating Q3 2022 financials because extinguishment of deferred underwriter commissions was incorrectly recorded as a gain instead of a credit to shareholders' deficit.
- No impact on liquidity, cash flows, trust account or operating expenses — only a classification change.
- Identified a material weakness in internal control over financial reporting and ineffective disclosure controls for the affected period.
- Restatement will be included in the 2022 10-K; audit committee and independent auditor have been informed.
- One underwriter waived its 50% share of deferred underwriting commissions in August 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1838821/000114036123016524/0001140361-23-016524-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1838821/000114036123016524/brhc10050928_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-016524

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer